Investment
Features
FeesSafety
Academy
More
Pluang+

Twenty One Capital reports $414M Q2 loss, shifts focus from Bitcoin holding to cash flow businesses

Market News
11 Aug 2026
Crypto Briefing
View Source
Bearish
pluang ai news

Twenty One Capital posted a $414 million loss in Q2, prompting new CEO Raphael Zagury to pivot the company from a pure Bitcoin treasury model to building operational businesses that generate cash flow. The firm, backed by Tether, will now focus on Bitcoin-native platforms and services to create revenue streams beyond holding Bitcoin. This change also ends previous merger plans with Strike and Elektron Energy. The shift aims to reduce volatility risks and justify the company's equity premium by offering more than just Bitcoin exposure.

More News

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
26 minutes ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
37 minutes ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
1 hour ago
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...

Market News
Bullish
1 hour ago
TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental posts 118% revenue growth and beats EPS estimates despite ongoing losses

TOMI Environmental Solutions reported a 118% year-over-year revenue increase to $2.25 million, surpassing analyst estimates of $1.84 million. The company also beat EPS expectations with a loss of $0.05 per share, better than the anticipated loss of $...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App